Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

11241. Endobronchial ultrasound for lung cancer diagnosis and staging: a review of the clinical- and cost-effectiveness

Endobronchial ultrasound for lung cancer diagnosis and staging: a review of the clinical- and cost-effectiveness Endobronchial ultrasound for lung cancer diagnosis and staging: a review of the clinical- and cost-effectiveness Endobronchial ultrasound for lung cancer diagnosis and staging: a review of the clinical- and cost-effectiveness Ho C, Clark M, Argaez C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation Ho C, Clark M, Argaez C. Endobronchial ultrasound for lung cancer diagnosis and staging: a review of the clinical- and cost-effectiveness . Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2009 Authors' objectives To review the clinical and cost effectiveness of using endobronchial ultrasound (EBUS) in diagnosing and staging lung cancer. Authors' conclusions Current evidence indicates that endobronchial

2009 Health Technology Assessment (HTA) Database.

11242. Nanoparticle-based cancer therapies: Albumin-bound paclitaxel

Nanoparticle-based cancer therapies: Albumin-bound paclitaxel Nanoparticle-based cancer therapies: Albumin-bound paclitaxel Nanoparticle-based cancer therapies: Albumin-bound paclitaxel Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Report may be purchased from Citation Nanoparticle-based cancer therapies: Albumin-bound paclitaxel . Lansdale: HAYES, Inc.. 2009 Authors (...) ' objectives Nanoparticle-albumin-bound paclitaxel (nab-paclitaxel; Abraxane®) is a chemotherapeutic drug that is administered alone or in combination with other agents for the purpose of delaying disease progression and prolonging survival in patients who have cancer. Nab-paclitaxel differs from standard paclitaxel in that it is a colloidal suspension of 130-nanometer (nm) albumin-bound nanoparticles of paclitaxel and is, therefore, free of solvents. The goal of this new nanotechnology based formulation

2009 Health Technology Assessment (HTA) Database.

11243. PathFinderTG test for pancreatic cancer

PathFinderTG test for pancreatic cancer PathFinderTG test for pancreatic cancer PathFinderTG test for pancreatic cancer Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Report may be purchased from Citation PathFinderTG test for pancreatic cancer . Lansdale: HAYES, Inc.. 2009 Authors' objectives Prior to the 1980s, pancreatic cysts were relatively uncommon and, when

2009 Health Technology Assessment (HTA) Database.

11244. ColoSure Colorectal Cancer Detection Test

ColoSure Colorectal Cancer Detection Test ColoSure colorectal cancer detection test ColoSure colorectal cancer detection test Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Report may be purchased from Citation ColoSure colorectal cancer detection test . Lansdale: HAYES, Inc.. 2009 Authors' objectives Colorectal cancer (CRC) is the third most common cancer in both men (...) testing (FOBT), flexible sigmoidoscopy, and colonoscopy. Recently, the feasibility of screening for CRC by analyzing sequence variants in DNA extracted from fecal specimens has been studied. Several different fecal DNA tests have been proposed that use a variety of markers, including genes associated with chromosomal and DNA instability; aberrant methylation of gene promoter sequences; and the presence of long DNA fragments. The Colosure Colorectal Cancer Detection Test is 1 such test that assesses

2009 Health Technology Assessment (HTA) Database.

11245. BRCA1 and BRCA2 sequence variant analysis for susceptibility to hereditary ovarian cancer

BRCA1 and BRCA2 sequence variant analysis for susceptibility to hereditary ovarian cancer BRCA1 and BRCA2 sequence variant analysis for susceptibility to hereditary ovarian cancer BRCA1 and BRCA2 sequence variant analysis for susceptibility to hereditary ovarian cancer Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Report may be purchased from Citation BRCA1 and BRCA2 (...) sequence variant analysis for susceptibility to hereditary ovarian cancer . Lansdale: HAYES, Inc.. 2009 Authors' objectives It is estimated that more than 21,000 women will be diagnosed with ovarian cancer in the United States in 2009, and more than 14,000 women will die from the disease. It has also been estimated that approximately 10% of patients with ovarian cancer, the vast majority of who have epithelial tumors, carry germline variants in 1 of 2 hereditary breast and ovarian cancer genes: BRCA1

2009 Health Technology Assessment (HTA) Database.

11246. Positron Emission Tomography (PET) for monitoring and prognosis of lung cancer

Positron Emission Tomography (PET) for monitoring and prognosis of lung cancer Positron Emission Tomography (PET) for monitoring and prognosis of lung cancer Positron Emission Tomography (PET) for monitoring and prognosis of lung cancer Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Report may be purchased from Citation Positron Emission Tomography (PET) for monitoring (...) and prognosis of lung cancer . Lansdale: HAYES, Inc.. 2009 Authors' objectives Positron emission tomography (PET) is a 3-dimensional (3D) imaging technique that evaluates the level of physiologic and biochemical activity within tissue cells by measuring the distribution of an injected or inhaled radiotracer. Due to differences in metabolic rates, the concentration of radiotracers within cancerous cells differs from the concentration in surrounding normal tissue cells. PET has been proposed as a tool

2009 Health Technology Assessment (HTA) Database.

11247. Clinical utility of cancer family history collection in primary care

Clinical utility of cancer family history collection in primary care Clinical utility of cancer family history collection in primary care Clinical utility of cancer family history collection in primary care Wilson B, Qureshi N, Little J, Santaguida P, Carroll J, Allanson J, Keshavarz H, Raina P. Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation Wilson B, Qureshi N, Little J, Santaguida P, Carroll J, Allanson J, Keshavarz H, Raina P.. Clinical utility of cancer family history collection in primary care. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 179. 2009 Authors' conclusions Our review indicates a very limited evidence base with which to address all four of the research questions: 1.The few evaluations of cancer risk prediction models do not suggest useful individual

2009 Health Technology Assessment (HTA) Database.

11248. Reclast (Novartis Pharmaceuticals Corp.) for bone loss prevention during breast cancer chemotherapy

Reclast (Novartis Pharmaceuticals Corp.) for bone loss prevention during breast cancer chemotherapy Reclast (Novartis Pharmaceuticals Corp.) for bone loss prevention during breast cancer chemotherapy Reclast (Novartis Pharmaceuticals Corp.) for bone loss prevention during breast cancer chemotherapy Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Report may be purchased (...) from Citation Reclast (Novartis Pharmaceuticals Corp.) for bone loss prevention during breast cancer chemotherapy . Lansdale: HAYES, Inc.. 2009 Authors' objectives It has been estimated that 13% of women in the United States will develop breast cancer during their lifetimes. In many women, growth of breast cancer can be reduced by blocking the formation of estrogen with drugs known as aromatase inhibitors. Although these drugs improve the survival of women who have estrogen-responsive breast cancer

2009 Health Technology Assessment (HTA) Database.

11249. Gefitinib for the second-line treatment of locally advanced or metastatic non-small-cell lung cancer (terminated appraisal)

Gefitinib for the second-line treatment of locally advanced or metastatic non-small-cell lung cancer (terminated appraisal) Gefitinib for the second-line treatment of locally advanced or metastatic non-small-cell lung cancer (terminated appraisal) Gefitinib for the second-line treatment of locally advanced or metastatic non-small-cell lung cancer (terminated appraisal) National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health (...) technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Health and Clinical Excellence. Gefitinib for the second-line treatment of locally advanced or metastatic non-small-cell lung cancer (terminated appraisal) London: National Institute for Health and Clinical Excellence (NICE). Technology Appraisal Guidance 175. 2009 Authors' conclusions NICE is unable to recommend the use in the NHS of gefitinib for the second-line

2009 Health Technology Assessment (HTA) Database.

11250. Cetuximab for the first-line treatment of metastatic colorectal cancer

Cetuximab for the first-line treatment of metastatic colorectal cancer Cetuximab for the first-line treatment of metastatic colorectal cancer Cetuximab for the first-line treatment of metastatic colorectal cancer National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Health and Clinical (...) Excellence. Cetuximab for the first-line treatment of metastatic colorectal cancer. London: National Institute for Health and Clinical Excellence (NICE). Technology Appraisal Guidance 176. 2009 Authors' conclusions Cetuximab in combination with 5-fluorouracil (5-FU), folinic acid and oxaliplatin (FOLFOX), within its licensed indication, is recommended for the first-line treatment of metastatic colorectal cancer only when all of the following criteria are met: • The primary colorectal tumour has been

2009 Health Technology Assessment (HTA) Database.

11251. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer?

Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Fuccio L, Zagari R M, Eusebi L H, Laterza L, Cennamo V, Ceroni L, Grilli D, Bazzoli F CRD summary This generally well-conducted review concluded that Helicobacter pylori eradication treatment appeared (...) to reduce gastric cancer risk, but the generalisability of the findings may be limited. Also, they are based on evidence of variable reliability. These conclusions are an accurate reflection the results of the review and appear to be reliable. Authors' objectives To determine whether Helicobacter pylori eradication treatment can reduce the risk of gastric cancer. Searching PubMed, EMBASE, the Cochrane Library and Google Scholar were searched without language, completion or publication status restriction

2009 DARE.

11252. Acupuncture for treating hot flashes in breast cancer patients: a systematic review

Acupuncture for treating hot flashes in breast cancer patients: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

11253. Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach

Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

11254. Late morbidity associated with a tumour-negative sentinel lymph node biopsy in primary breast cancer patients: a systematic review

Late morbidity associated with a tumour-negative sentinel lymph node biopsy in primary breast cancer patients: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

11255. Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a literature-based meta-analysis Full Text available with Trip Pro

Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a literature-based meta-analysis Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a literature-based meta-analysis Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a literature-based meta-analysis Russo A, Rizzo S, Fulfaro F, Adamo V, Santini D (...) , Vincenzi B, Gebbia N, Carreca I CRD summary This review assessed the efficacy and tolerability of gemcitabine-based doublets compared with single-agent chemotherapy in elderly patients with advanced non-small cell lung cancer. The authors concluded that gemcitabine-based doublets appeared to be effective and feasible, but further research is needed. Unclear trial quality and potential methodological limitations in the review process means that the reliability of this conclusion is unclear. Authors

2009 DARE.

11256. Efficacy of intensified chemotherapy with hematopoietic progenitors in small-cell lung cancer: a meta-analysis of the published literature

Efficacy of intensified chemotherapy with hematopoietic progenitors in small-cell lung cancer: a meta-analysis of the published literature Efficacy of intensified chemotherapy with hematopoietic progenitors in small-cell lung cancer: a meta-analysis of the published literature Efficacy of intensified chemotherapy with hematopoietic progenitors in small-cell lung cancer: a meta-analysis of the published literature Jiang J, Shi HZ, Deng JM, Liang QL, Qin SM, Wu C CRD summary The authors concluded (...) with haematopoietic progenitors (ICHP) in patients with small-cell lung cancer. Searching MEDLINE and EMBASE (both from inception up to October 2008) were searched for English-only full text publications. Search terms were reported. Reference lists of included studies and related publications were handsearched. Study selection Randomised phase II and III clinical trials that compared ICHP to control chemotherapy without haematopoietic progenitors in patients with small-cell lung cancer were eligible for inclusion

2009 DARE.

11257. Risk of second malignant neoplasms among childhood cancer survivors treated with radiotherapy: meta-analysis of nine epidemiological studies

Risk of second malignant neoplasms among childhood cancer survivors treated with radiotherapy: meta-analysis of nine epidemiological studies Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

11258. Implementation of integrated care for patients with cancer: a systematic review of interventions and effects

Implementation of integrated care for patients with cancer: a systematic review of interventions and effects Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

11259. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis

Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

11260. Timeliness of care in patients with lung cancer: a systematic review

Timeliness of care in patients with lung cancer: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.